Figure 2. Change in PON activity from baseline to 6 months (least square mean). This figure depicts model-based least square mean PON activities (PON1—panel A, LAC—panel B, ARYL—panel C) from baseline to 6 months after initiation of a new biologic. TCZ led to significant increases in all three PON1 activity domains. ABA, abatacept; ARYL, arylesterase; LAC, lactonase; PON, paraoxonase; RTX, rituximab; TCZ, tocilizumab; TNFi, tumour necrosis factor inhibitor.